MERRIMACK PHARMACEUTICALS IN (MACK)
US5903282094 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 5.99M | 19.40M | 14.20M | 14.00M | 16.60M | |||
| Marketable Securities | 12.89M | N/A | N/A | N/A | 0.00 | |||
| Receivables | N/A | N/A | N/A | N/A | N/A | |||
| Inventories | N/A | N/A | N/A | N/A | N/A | |||
| Other Current Assets | 309.00K | 400.00K | 500.00K | 2.50M | 2.10M | |||
| Total Current Assets | 19.18M | 19.80M | 14.70M | 16.50M | 18.70M | |||
| Non-Current Assets | ||||||||
| PPE Net | N/A | N/A | N/A | N/A | 0.00 | |||
| Investments And Advances | N/A | N/A | N/A | N/A | 0.00 | |||
| Goodwill | N/A | N/A | N/A | N/A | N/A | |||
| Intangibles | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 4.00K | 0.00 | 100.00K | 200.00K | 1.40M | |||
| Total Non-Current Assets | 4.00K | 0.00 | 0.00 | 300.00K | 1.40M | |||
| TOTAL ASSETS | 19.19M | 19.80M | 14.70M | 16.80M | 20.10M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 367.00K | 400.00K | 400.00K | 600.00K | 1.10M | |||
| Accounts Payable | 74.00K | 200.00K | 100.00K | 100.00K | 300.00K | |||
| Other Current Liabilities | N/A | N/A | N/A | 0.00 | 1.40M | |||
| Total Current Liabilities | 441.00K | 600.00K | 600.00K | 800.00K | 2.80M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Deferred Taxes/Income | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Liabilities | N/A | N/A | N/A | N/A | 0.00 | |||
| Total Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| TOTAL LIABILITIES | 441.00K | 600.00K | 600.00K | 800.00K | 2.80M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -548.82M | -547.60M | -546.10M | -543.60M | -540.60M | |||
| Additional Paid In Capital | 566.22M | 565.50M | 558.90M | 558.30M | 556.60M | |||
| Minority Interest | N/A | N/A | N/A | N/A | N/A | |||
| Common Shares | 1.34M | 1.30M | 1.30M | 1.30M | 1.30M | |||
| Other Shareholders' Equity | N/A | N/A | N/A | 0.00 | 0.00 | |||
| Shares Outstanding | 14.35M | 14.20M | 13.40M | 13.40M | 13.40M | |||
| Tangible Book Value per Share | 1.31 | 1.35 | 1.06 | 1.19 | 1.29 | |||
| Total Shareholders' Equity | 18.75M | 19.20M | 14.20M | 16.00M | 17.30M | |||
| TOTAL LIABILITIES AND EQUITY | 19.19M | 19.80M | 14.70M | 16.80M | 20.10M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 43.50 | 33.00 | 24.50 | 20.63 | 6.68 | |||
| Return On Assets (ROA) | -6.15% | -7.58% | -17.01% | -17.86% | -86.07% | |||
| Return On Equity (ROE) | -6.30% | -7.81% | -17.61% | -18.75% | -100.00% | |||
All data in USD